{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:41:29Z","timestamp":1782780089517,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01173-5","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:04:24Z","timestamp":1767024264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice"],"prefix":"10.1186","volume":"23","author":[{"given":"Hedda C.","family":"Lamers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Van Nieuwenhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"van Royen-Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost F.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"1173_CR1","doi-asserted-by":"publisher","unstructured":"Martini A, Lovell DJ, Albani S, Brunner HI, Hyrich KL, Thompson SD, Ruperto N. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):5. https:\/\/doi.org\/10.1038\/s41572-021-00332-8. PMID: 35087087.","DOI":"10.1038\/s41572-021-00332-8"},{"key":"1173_CR2","doi-asserted-by":"publisher","unstructured":"Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(11)60244-4. PMID: 21684384.","DOI":"10.1016\/S0140-6736(11)60244-4"},{"key":"1173_CR3","doi-asserted-by":"publisher","unstructured":"Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2005;52(2):413\u201342, vi. https:\/\/doi.org\/10.1016\/j.pcl.2005.01.007. PMID: 15820374.","DOI":"10.1016\/j.pcl.2005.01.007"},{"key":"1173_CR4","doi-asserted-by":"publisher","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003. Epub 2013 Nov 6. PMID: 24210707.","DOI":"10.1016\/j.jbspin.2013.09.003"},{"key":"1173_CR5","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132. PMID: 14760812."},{"key":"1173_CR6","doi-asserted-by":"publisher","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019;71(6):846\u201363. https:\/\/doi.org\/10.1002\/art.40884. Epub 2019 Apr 25. PMID: 31021537; PMCID: PMC6561114.","DOI":"10.1002\/art.40884"},{"key":"1173_CR7","doi-asserted-by":"publisher","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74(4):553\u201369. https:\/\/doi.org\/10.1002\/art.42037. Epub 2022 Mar 1. PMID: 35233993; PMCID: PMC10161784.","DOI":"10.1002\/art.42037"},{"key":"1173_CR8","doi-asserted-by":"publisher","unstructured":"Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168. https:\/\/doi.org\/10.1186\/s13075-019-1950-7. PMID: 31287015; PMCID: PMC6615271.","DOI":"10.1186\/s13075-019-1950-7"},{"key":"1173_CR9","doi-asserted-by":"publisher","unstructured":"Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020;20(7):725\u201340. https:\/\/doi.org\/10.1080\/14712598.2020.1733524. Epub 2020 Mar 2. PMID: 32116038.","DOI":"10.1080\/14712598.2020.1733524"},{"key":"1173_CR10","unstructured":"Enbrel | Initial marketing authorisation documents - EPAR - Scientific Discussion [Internet]. 2006 Oct [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enbrel"},{"key":"1173_CR11","unstructured":"Humira-H-C-481-II-39\u202f: EPAR - Assessment Report - Variation [Internet]. 2008 Oct [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"key":"1173_CR12","unstructured":"Cimzia | European Medicines Agency (EMA) [Internet]. [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cimzia-0"},{"key":"1173_CR13","doi-asserted-by":"publisher","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030. Epub 2018 Apr 11. PMID: 29643108.","DOI":"10.1136\/annrheumdis-2018-213030"},{"key":"1173_CR14","unstructured":"Orencia\u202f: EPAR - Procedural steps taken and scientific information after authorisation [Internet]. 2024 Jun [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orencia"},{"key":"1173_CR15","unstructured":"RoActemra\u202f: EPAR - Procedural steps taken and scientific information after authorisation [Internet]. 2024 Jun [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roactemra"},{"key":"1173_CR16","doi-asserted-by":"publisher","unstructured":"Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9(9):557\u201363. https:\/\/doi.org\/10.1038\/nrrheum.2013.105. Epub 2013 Jul 9. PMID: 23838613.","DOI":"10.1038\/nrrheum.2013.105"},{"key":"1173_CR17","doi-asserted-by":"publisher","unstructured":"Lipstein EA, Brinkman WB, Sage J, Lannon CM, Morgan Dewitt E. Understanding treatment decision making in juvenile idiopathic arthritis: a qualitative assessment. Pediatr Rheumatol Online J. 2013;11(1):34. https:\/\/doi.org\/10.1186\/1546-0096-11-34. PMID: 24079577; PMCID: PMC3849714.","DOI":"10.1186\/1546-0096-11-34"},{"key":"1173_CR18","doi-asserted-by":"publisher","unstructured":"Currie GR, Pham T, Twilt M, IJzerman MJ, Hull PM, Kip MMA, et al. Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Patient. 2022;15(5):599\u2013609. https:\/\/doi.org\/10.1007\/s40271-022-00575-x. Epub 2022 Mar 24. PMID: 35322390.","DOI":"10.1007\/s40271-022-00575-x"},{"key":"1173_CR19","doi-asserted-by":"publisher","unstructured":"Yue X, Huang B, Hincapie AL, Wigle PR, Qiu T, Li Y, et al. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis. Paediatr Drugs. 2021;23(2):171\u201382. https:\/\/doi.org\/10.1007\/s40272-021-00436-4. Epub 2021 Mar 2. Erratum in: Paediatr Drugs. 2021;23(3):315. https:\/\/doi.org\/10.1007\/s40272-021-00447-1. PMID: 33651370.","DOI":"10.1007\/s40272-021-00436-4"},{"key":"1173_CR20","doi-asserted-by":"publisher","unstructured":"Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, et al. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Pediatr Rheumatol Online J. 2022;20(1):25. https:\/\/doi.org\/10.1186\/s12969-022-00682-x. PMID: 35410419; PMCID: PMC8996666.","DOI":"10.1186\/s12969-022-00682-x"},{"key":"1173_CR21","doi-asserted-by":"publisher","unstructured":"Chaudoir SR, Dugan AG, Barr CH. Measuring factors affecting implementation of health innovations: a systematic review of structural, organizational, provider, patient, and innovation level measures. Implement Sci. 2013;8:22. https:\/\/doi.org\/10.1186\/1748-5908-8-22. PMID: 23414420; PMCID: PMC3598720.","DOI":"10.1186\/1748-5908-8-22"},{"key":"1173_CR22","doi-asserted-by":"publisher","unstructured":"Dunn AG, Braithwaite J, Gallego B, Day RO, Runciman W, Coiera E. Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. BMC Health Serv Res. 2012;12:248. https:\/\/doi.org\/10.1186\/1472-6963-12-248. PMID: 22876867; PMCID: PMC3441328.","DOI":"10.1186\/1472-6963-12-248"},{"key":"1173_CR23","doi-asserted-by":"publisher","unstructured":"Medlinskiene K, Tomlinson J, Marques I, Richardson S, Stirling K, Petty D. Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021;21(1):1198. https:\/\/doi.org\/10.1186\/s12913-021-07196-4. PMID: 34740338; PMCID: PMC8570007.","DOI":"10.1186\/s12913-021-07196-4"},{"key":"1173_CR24","doi-asserted-by":"publisher","unstructured":"Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74(7):1379\u201386. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204641. Epub 2014 Mar 18. PMID: 24641940.","DOI":"10.1136\/annrheumdis-2013-204641"},{"key":"1173_CR25","doi-asserted-by":"publisher","unstructured":"Nguyen K, Barsalou J, Basodan D, Batthish M, Benseler SM, Berard RA, et al. A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry. Rheumatology (Oxford). 2024;63(SI2):SI173\u2013SI179. https:\/\/doi.org\/10.1093\/rheumatology\/kead560. Erratum in: Rheumatology (Oxford). 2024;63(SI2):SI269. https:\/\/doi.org\/10.1093\/rheumatology\/kead686. PMID: 37851400; PMCID: PMC11381684.","DOI":"10.1093\/rheumatology\/kead560"},{"key":"1173_CR26","unstructured":"Humira-H-C-481-II-0081-G\u202f: EPAR - Assessment Report - Variation [Internet]. 2011 May [cited 2024 Sep 17]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"key":"1173_CR27","doi-asserted-by":"publisher","unstructured":"Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189\u201395. https:\/\/doi.org\/10.1093\/rheumatology\/keq308. Epub 2010 Nov 3. PMID: 21047801.","DOI":"10.1093\/rheumatology\/keq308"},{"key":"1173_CR28","doi-asserted-by":"publisher","unstructured":"Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford). 2013;52(9):1674\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/ket170. Epub 2013 Jun 4. PMID: 23740187.","DOI":"10.1093\/rheumatology\/ket170"},{"key":"1173_CR29","unstructured":"Amgevita | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amgevita"},{"key":"1173_CR30","unstructured":"Tyenne | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tyenne"},{"key":"1173_CR31","unstructured":"Federatie Medisch Specialisten. Richtlijn - NVK - Juveniele idiopathische artritis, medicamenteuze behandeling van kinderen met [Internet]. 2018 [cited 2024 Sep 12]. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/juveniele_idiopathische_artritis_jia\/startpagina_-_jia.html"},{"key":"1173_CR32","doi-asserted-by":"publisher","unstructured":"Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, et al. PRCSG Advisory Council and the CARRA Registry Investigators. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2020;72(11):1945\u201351. https:\/\/doi.org\/10.1002\/art.41390. Epub 2020 Oct 8. PMID: 32524767; PMCID: PMC7722045.","DOI":"10.1002\/art.41390"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01173-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01173-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:04:25Z","timestamp":1767024265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-025-01173-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01173-5","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used anonymized data from the Electronic Medical Records (EMR) of the Wilhelmina Children\u2019s Hospital in Utrecht. As the data was anonymized and could not be linked to individual patients, ethical approval and informed consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.F. has received a research grant from Pfizer, a consultancy fee from Pfizer, and serves on the Data Monitoring Committee (DSMB) for Bristol Myers Squibb. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}